How Secukinumab works

Secukinumab (Secukinumab) is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines. Indicated for patients 6 years and older with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy. It is also indicated for patients 2 years and older with active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), active nonradiographic axial spondyloarthritis (nr-axSpA), and patients 4 years and older with active enthesitis-associated arthritis (ERA).